CRISPR Therapeutics AG (Nasdaq: CRSP)

https://www.crisprtx.com

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. *

	Start	2013-01-01 established
	Group	CRISPR Therapeutics (Group)
	Industry	CRISPR gene editing technology

	Street	14 Baarerstr.
	City	6300 Zug ZG
	Tel	+41-41-561-3277
		Address record changed: 2025-07-05

Basic data	Employees	D: 101 to 500 (2024-12-31)
	Currency	USD
	Annual sales	37,314,000 (revenue, total, consolidated (2024) 2024-12-31)
	Profit	-366,252,000 (2024-12-31)
	Cash	1,903,826,000 (2024-12-31)

		* Document for »About Section«: CRISPR Therapeutics AG. (5/29/25). "Press Release: CRISPR Therapeutics to Participate in Upcoming Investor Conferences". Zug & Boston, MA.

		Record changed: 2026-05-02

Picture EBD Group BIO-Europe 2026 Köln Cologne to 31 Jul 650x200px

More documents for CRISPR Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)